Revisiones en Cáncer 00074 / http://dx.doi.org/10.20960/revcancer.00074

Resumen| PDF

Revisión

Carcinoma escamoso localmente avanzado e irresecable

Julio José Lambea Sorrosal, María Zapata García, Alba Moratiel Pellitero, Karla Andrea Osorio Macassi, Isabel Pajares Bernad, Inés Ruiz Moreno, Sara Esteras Per

Prepublicado: 2024-05-16

Publicado: 2024-07-03

VOLUMEN 38, NÚM. 2, marzo-abril (2024), PAG. 54-59

Logo Descargas Número de descargas: 4314 Logo Visitas Número de visitas: 235 Citas Citas: 0

Compártelo:

El panorama del tratamiento para el carcinoma de cabeza y cuello localmente avanzado (CECCLA) no resecable se ha mantenido con escasos cambios durante más de 20 años. El tratamiento estándar actual para los pacientes con CECCLA no resecable que son elegibles para recibir cisplatino es la quimiorradioterapia: cisplatino 100 mg/m2 cada 3 semanas (3 ciclos) más tratamiento fraccionado estándar con radioterapia de 70 Gy en 35 fracciones diarias de 2 Gy durante 7 semanas, aunque en los últimos años la radioterapia ha presentado grandes avances tecnológicos que permiten optimizar el esquema concomitante. En los últimos años la investigación se ha centrado en encontrar fármacos con igual o mayor efectividad que el cisplatino en pacientes que no son adecuados para recibirlo por distintos factores. El avance más relevante fue la utilización de cetuximab con radioterapia en esos casos y se ha investigado sobre distintas pautas de platino, combinaciones con inmunoterapia y se están desarrollando estudios con nuevos fármacos que actúan en la vía de la apoptosis como xevinapant con resultados prometedores.

Palabras Clave: Quimiorradioterapia. Cetuximab. Inmunoterapia. Apoptosis.

Descargar PDF

Bibliografía
Artículos Relacionados

Blanchard P, Landais C, Petit C, Zhang Q, Grégoire V, Tobias J, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH- NC): an update on 100 randomized trials and 19,248 patients, on behalf of MACH-NC Group. Ann Oncol 2016;27(Suppl 6):950.
DOI: 10.1093/annonc/mdw376.02

Spreafico A, Huang SH, Xu W, Granata R, Liu CS, Waldron JN, et al. Impact of cisplatin dose intensity on human papillomavirus-re- lated and -unrelated locally advanced head and neck squamous cell carcinoma. Eur J Cancer 2016;67:174-82.
DOI: 10.1016/j.ejca.2016.08.013

Szturz Petr, Wouters K. Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer. Front Oncol vol 9. 86
DOI: 10.3389/fonc.2019.00086

Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morri- son W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-8.
DOI: 10.1056/NEJMoa031317

Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:1937-44.
DOI: 10.1056/NEJMoa032646

Dunst J, Hildebrandt G, Becker-Schiebe M, Kuhnt T, Weykamp F, Richetti A, et al. Assessment of therapeutic compliance of patients treated with cisplatin plus radiotherapy in locally advanced squa- mous cell carcinoma of the head and neck -first results of the retrospective, anonymized, observational, European, multicenter COMPLY trial. Presented at: 6th Trends in Head and Neck Oncol- ogy; Nice, 2017.

Espeli V, Zucca E, Ghielmini M, Giannini O, Salatino A, Martucii F, et al. Weekly and 3-weekly cisplatin concurrent with intensity-mod- ulated radiotherapy in locally advanced head and neck squamous cell cancer. Oral Oncol 2012;48(3):266-71.
DOI: 10.1016/j.oraloncology.2011.10.005

Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
DOI: 10.1056/NEJMoa053422

Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21-8.
DOI: 10.1016/S1470-2045(09)70311-0

Bernier J, Russi EG, Homey B, Merlano MC, Mesía R, Peyrade F, et al. Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grad- ing system and consensus management guidelines. Ann Oncol 2011;22:2191-200.
DOI: 10.1093/annonc/mdr139

Russi EG, Bensadoun RJ, Merlano MC, Bourhis J, Ricardi U, Giralt J, et al. Bio-radiation dermatitis: the need of a new grading. Ann Oncol 2013;24:2463-5.
DOI: 10.1093/annonc/mdt281

Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, et al. Radiotherapy plus cetuximab or cisplatin in human pap- illomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet 2019;393:40-50.
DOI: 10.1016/S0140-6736(18)32779-X

NCCN Guidelines. Available from: https://www.nccn.org/guide- lines/category_4

Espeli V, Zucca E, Ghielmini M, Giannini O, Salatino A, Martucii F, et al. Weekly and 3-weekly cisplatin concurrent with intensity-mod- ulated radiotherapy in locally advanced head and neck squamous cell cancer. Oncol Oral 2012;48:266-71.
DOI: 10.1016/j.oraloncology.2011.10.005

Mitra D, Choudhury K, Rashid MA. Concurrent chemotherapy in advanced head and neck carcinoma: A prospective randomized trial. Bangaladesh J Otorrinolaringol 2011;17:88-95.
DOI: 10.3329/bjo.v17i2.8847

Tsan DL, Lin CY, Kang CJ, Huang SF, Fan KH, Liao CT, et al. The comparison between weekly and three-weekly cisplatin delivered concurrently with radiotherapy for patients with postoperative high-risk squamous cell carcinoma of the oral cavity. Radiat Oncol 2012;7:215.
DOI: 10.1186/1748-717X-7-215

Kim R, Hahn S, Shin J, Ock C-Y, Kim M, Keam B, et al. The effect of induction chemotherapy using docetaxel, cisplatin, and fluoroura- cil on survival in locally advanced head and neck squamous cell carcinoma: a meta-analysis. Cancer Res Treat 2016;48(3):907-16.
DOI: 10.4143/crt.2015.359

Ghi MG, Paccagnella A, Ferrari D, Foa P, Alterio D, Codecà C, et al. Induction TPF followed by concomitant treatment versus concom- itant treatment alone in locally advanced head and neck cancer. A phase II-III trial. Ann Oncol 2017;28(9):2206-12.
DOI: 10.1093/annonc/mdx299

Hitt R, Grau JJ, López-Pousa A, Berrocal A, García-Girón C, Irigoyen A, et al. A randomized phase III trial comparing induction chemo- therapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol 2014;25(1):216-25.
DOI: 10.1093/annonc/mdt461

Hitt R, Mesía R, Lozano A, Iglesias Docampo L, Grau JJ, Taberna M, et al. Randomized phase 3 noninferiority trial of radiothera- py and cisplatin vs radiotherapy and cetuximab after docetax- el-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer. Oral Oncol 2022;134:106087.
DOI: 10.1016/j.oraloncology.2022.106087

Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degar- din M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357(17):1695-704.
DOI: 10.1056/NEJMoa071028

Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 2011;12(2):153-9.
DOI: 10.1016/S1470-2045(10)70279-5

Lacas B, Carmel A, Landais C, Wong SJ, Licitra L, Tobias JS, et al.; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiother Oncol 2021;156:281-93.
DOI: 10.1016/j.radonc.2021.01.013

Lee NY, Ferris RL, Psyrri A, Haddad RI, Tahara M, Bourhis J, et al. Avelumab plus standard-of-care chemoradiotherapy ver- sus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol 2021;22:450-62.
DOI: 10.1016/S1470-2045(20)30737-3

Machiels J, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, et al. Pembrolizumab plus concurrent chemoradiotherapy versus pla- cebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEY- NOTE-412): a randomised, double-blind, phase 3 trial. Lancet 2024;25(5):572-87.
DOI: 10.1016/S1470-2045(24)00100-1

Tao Y, Aupérin A, Sun X, Sire C, Martin L, Coutte A, et al. Ave- lumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH). Eur J Cancer 2020;141:21-9.
DOI: 10.1016/j.ejca.2020.09.008

Tao Y, Biau J, Sun XS, Sire C, Martin L, Alfonsi M, et al. Pembrolizum- ab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, rand- omized, phase II trial. Ann Oncol 2023;34(1):101-10.
DOI: 10.1016/j.annonc.2022.10.006

Haddad R, Wong DJ, et al. IMvoke010: randomized phase III study of atezolizumab (atezo) as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (SCCHN). Ann Oncol 2019;79 (Suppl 13):CT123-CT123.
DOI: 10.1158/1538-7445.AM2019-CT123

Sun XS, Tao Y, Le Tourneau C, Pointreau Y, Sire C, Kaminsky MC, et al. Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study. Lancet Oncol 2020;21:1173-87.
DOI: 10.1016/S1470-2045(20)30327-2

Bourhis J, Le Tourneau C, Calderon B, Martin L, Sire C, Pintreau Y, et al. 5-year overall survival (OS) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) treated with xevinapant + chemoradiotherapy (CRT) vs placebo + CRT in a randomized, phase II study. Ann Oncol 2022;33;Abstract LBA33.
DOI: 10.1016/j.annonc.2022.08.030

Revisión: Quimiorradiación del cáncer de esófago

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Quimioterapia en cáncer de esófago

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Líneas de investigación en cáncer de esófago

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Inmunoterapia en hepatocarcinoma

Publicado: 2022-07-28 / http://dx.doi.org/

Resumen | PDF

Revisión: Tratamiento médico del cáncer de estómago recurrente y metastásico en primera línea

Publicado: 2022-07-28 / http://dx.doi.org/

Resumen | PDF